[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632708":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":62,"collaborators":20,"id":64,"slug":20,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":20,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":20,"enrollmentInfo":72,"targetDuration":20,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":92,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},{"fullName":5,"class":6},"Exscientia AI Limited","INDUSTRY",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"EXS74539","EXPERIMENTAL",[12],"Drug: EXS74539",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"DRUG","Oral administration",[9],[19],"REC-4539",null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Exscientia AI Ltd.","CONTACT","385-374-1724","clinicaltrials@recursion.com",[28,42,52],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":20},"Start Lacn","RECRUITING","Los Angeles","California","90025","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-118.24368,34.05223,{"lat":40,"lon":39},{"facility":43,"status":30,"city":44,"state":45,"zip":46,"country":34,"countryCode":35,"cosmosGeoPoint":47,"geoPoint":51,"contacts":20},"START Dallas","Fort Worth","Texas","76104",{"type":37,"coordinates":48},[49,50],-97.32085,32.72541,{"lat":50,"lon":49},{"facility":53,"status":30,"city":54,"state":55,"zip":56,"country":34,"countryCode":35,"cosmosGeoPoint":57,"geoPoint":61,"contacts":20},"START Mountain Region","West Valley City","Utah","84119",{"type":37,"coordinates":58},[59,60],-112.00105,40.69161,{"lat":60,"lon":59},{"type":63,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100632708",false,"NCT07517198","Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors","A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Efficacy of EXS74539 as Monotherapy in Participants With Select Solid Tumors","Key Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Histologically confirmed diagnosis of the following solid tumors:\n\n  * SCLC\n  * High grade neuroendocrine or small cell carcinomas of non-lung origin\n  * Non-small cell lung cancer \\[NSCLC\\]\n  * Prostate cancer\n  * Ovarian cancer\n  * Renal carcinoma \\[clear and non-clear cell\\]\n  * Head and neck squamous cell carcinoma\n  * Hepatic cancer\n  * Gastric cancer\n  * Triple-negative breast cancer \\[TNBC\\]\n* Participant disease should have progressed, relapsed or the participants should have been intolerant to at least one prior standard systemic therapy for their respective underlying malignancy.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n\nKey Exclusion Criteria:\n\n* Any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study.\n* Symptomatic brain metastases, leptomeningeal metastases, or spinal cord compression due to disease. Participants with brain metastases must be clinically stable and off corticosteroids and anticonvulsants for ≥1 month prior to study treatment and not require any specific intervention for brain metastases.\n* Active and clinically significant infection requiring systemic antibacterial, antiviral, or antifungal therapy \\\u003C7 days of the first scheduled dose of the study treatment.\n* Significant cardiac abnormalities.\n* Major surgery within 28 days prior to the start of study treatment.\n\nNote: Other protocol-defined inclusion and exclusion criteria may apply.","ALL","18 Years",{"count":73,"type":74},40,"ESTIMATED","INTERVENTIONAL",[77],"PHASE1","The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.",[80,81,82,83,84,85,86,87,88,89,90,91],"Solid Tumor","Small Cell Lung Cancer (SCLC)","High Grade Neuroendocrine Cancer","Small Cell Carcinomas of Non-lung Origin","Non-small Cell Lung Cancer (NSCLC)","Prostate Cancer","Ovarian Cancer","Renal Carcinoma (Clear and Non-clear Cell)","Head and Neck Squamous Cell Carcinoma (HNSCC)","Hepatic Cancer","Gastric Cancer","Triple-negative Breast Cancer (TNBC)",[93,81,94,95,96,97,98,99,100,101,102,103,104,9,19],"Solid Tumors","High grade neuroendocrine cancer","Small cell carcinomas of non-lung origin","Non-small cell lung cancer (NSCLC)","Prostate cancer","Ovarian cancer","Renal carcinoma (clear and non-clear cell)","Head and neck squamous cell carcinoma (HNSCC)","Hepatic cancer","Gastric cancer","Triple-negative breast cancer (TNBC)","LSD1 inhibitor","2026-06-09",{"date":107,"type":108},"2026-06-10","ACTUAL",{"date":110,"type":108},"2026-04-13",{"date":112,"type":74},"2029-03",{"name":114,"class":6},"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",3]